Atlas Trials

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

Clinical trial NCT00412646 · COMPLETED

Trial details

NCT number
NCT00412646
Sponsor
Tibotec Pharmaceuticals, Ireland
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Anti-Retroviral AgentsHIV-1
Start date
2002-06-01
Enrollment
260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.